DV
Dividend Vision

BRTX — BioRestorative Therapies Inc

BioRestorative Therapies Inc (BRTX)

Its deepest 1-year drawdown was 90.8%.

BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily focused on adult stem cell treatments for spine/disc disease and metabolic disorders. The company's pipeline includes BRTX-100, a cell therapy candidate for non-surgical treatment of disc disorders, and ThermoStem, a cell-based therapy targeting obesity, along with a commercial biocosmeceutical platform and investigational delivery devices. The company does not currently distribute dividends and is oriented toward development-stage therapeutics rather than income generation.

BRTX key facts

Asset type
Stock
Asset class
Equity
Inception date
12/19/1997
Last close
$0.23
Market cap
$8,512,257
Average volume
162000.0
Beta
0.636
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.06